Mariaelena Capone

List of Publications by Year
in descending order

59	2,865	279798	233421
papers	citations	23 h-index	45 g-index

61	61	61	5371
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Frontiers in Immunology, 2022, 13, 811131.	4.8	6
2	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
3	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Scientific Reports, 2022, 12, 5448.	3.3	5
4	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	4.4	6
5	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. International Journal of Molecular Sciences, 2021, 22, 1801.	4.1	20
6	The Ratio of GrzB+ â˜’ FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers, 2021, 13, 2325.	3.7	7
7	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 2021, 13, 4164.	3.7	5
8	Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytesâ€™ iTNF-Î± Expression. Biology, 2021, 10, 735.	2.8	4
9	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine, 2020, 18, 121.	4.4	29
10	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods in Enzymology, 2020, 635, 21-31.	1.0	2
11	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
12	Identification of potential predictive biomarkers of rapid progression and rapid response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients.. Journal of Clinical Oncology, 2020, 38, e22068-e22068.	1.6	0
13	Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.. Journal of Clinical Oncology, 2020, 38, e22008-e22008.	1.6	0
14	Abstract 5529: Proteomic profiling of FFPE tumors samples from melanoma subjects treated with anti-PD-1 immunotherapy identifies proteins associated with response to treatment. , 2020, , .		0
15	761â€…Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. , 2020, , .		0
16	229â€…Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. , 2020, , .		0
17	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers, 2019, 11, 1425.	3.7	22
18	Enzyme activity of circulating CD73 in human serum. Methods in Enzymology, 2019, 629, 257-267.	1.0	3

#	Article	IF	Citations
19	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Scientific Reports, 2019, 9, 7449.	3.3	43
20	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
21	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunology Research, 2019, 7, 841-852.	3.4	47
22	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunology, Immunotherapy, 2019, 68, 97-107.	4.2	61
23	CD73 activity and outcome of advanced melanoma patients treated with nivolumab. European Journal of Cancer, 2018, 92, S22.	2.8	0
24	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. OncoImmunology, 2018, 7, e1387706.	4.6	76
25	A Serum Protein Signature Associated with Outcome after Antiâ€“PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research, 2018, 6, 79-86.	3.4	61
26	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206.	4.6	43
27	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
28	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	4.4	2
29	Abstract 558: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma. , 2018, , .		2
30	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. OncoImmunology, 2017, 6, e1261242.	4.6	59
31	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	4.8	27
32	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine, 2017, 15, 244.	4.4	73
33	Proportions of blood-borne VÎ´1+ and VÎ´2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	2.8	54
34	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	7.0	146
35	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	7.1	99
36	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12

#	Article	IF	Citations
37	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	7.0	459
38	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	4.4	2
39	Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies. Cancer Letters, 2015, 357, 286-296.	7.2	11
40	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	4.4	15
41	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. Journal of Translational Medicine, 2015, 13, O8.	4.4	2
42	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology, 2015, 4, e1008842.	4.6	72
43	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	4.4	24
44	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. Journal of Translational Medicine, 2014, 12, O13.	4.4	1
45	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
46	Immunoscore as new possible approach for the classification of melanoma.. Journal of Clinical Oncology, 2014, 32, e20020-e20020.	1.6	1
47	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Journal of Translational Medicine, 2013, 11, 54.	4.4	104
48	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine, 2013, 11, 202.	4.4	31
49	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. , 2013, 1, .		1
50	BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. Journal of Clinical Oncology, 2012, 30, 2522-2529.	1.6	419
51	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
52	Abstract 3677: Pattern and distribution of BRAF/NRAS and P16CDKN2Amutations among primary an secondary lesions in melanoma patients. , 2012, , .		2
53	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncology Reports, 2011, 25, 1495-502.	2.6	19
54	Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients.. Journal of Clinical Oncology, 2011, 29, 8574-8574.	1.6	3

#	Article	IF	Citations
55	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-Î± 2b treatment. Journal of Translational Medicine, 2010, 8, 76.	4.4	39
56	Characterization of a Novel Polymorphism in PPARG Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-7.	3.0	36
57	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Letters, 2009, 274, 331-336.	7.2	30
58	Main roads to melanoma. Journal of Translational Medicine, 2009, 7, 86.	4.4	157
59	9320 Treatment with intravenous High Dose Interferon (HDI) is able to reduce levels of circulating regulatory T (Treg) cells in melanoma patients. European Journal of Cancer, Supplement, 2009, 7, 583.	2.2	0